Lakewood-Amedex Biotherapeutics Stock Forecast
NASDAQ: LABTHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
LABT analyst consensus
Consensus
strong_buy
Avg. price target
$12.00+1415.15%
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
The average 12-month price target is $12.00, with a high estimate of $12.00 and a low estimate of $12.00. The average target implies upside of 1415.2% from the current price of $0.792. The spread between the highest and lowest targets is 0.0%, a relatively narrow range.
Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for LABT.
Summary generated from market data by MetaCap's automated system. Methodology
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $12.00 | +1415.15% |
| Average target | $12.00 | +1415.15% |
| High target | $12.00 | +1415.15% |
How analysts view Lakewood-Amedex Biotherapeutics's peers
| Company | Consensus | Price | Avg. target | Implied move |
|---|---|---|---|---|
| CRIS | none | 0.7094 | $42.67 | +5914.94% |